Physician profile
Patricia E Strieter
NPI 1902121965
$3,105.22
in general payments reported to CMS, 2019-2025
19 companies · $862 in 2025
The $862 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $696 · 2024: $1,199 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.07 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $414.77 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.92 | 2022-2025 | Caplyta |
| Lundbeck LLC | $224.87 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $221.69 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $209.70 | 2022-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $206.31 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $119.30 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $85.04 | 2024-2025 | Invega Sustenna |
| Corium, LLC | $73.85 | 2022-2023 | Azstarys |
| Validus Pharmaceuticals LLC | $46.10 | 2022-2023 | Equetro |
| Axsome Therapeutics, INC. | $44.73 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $38.30 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $28.61 | 2022-2025 | Trintellix |
| Biogen, INC. | $26.70 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $24.99 | 2024 | |
| Tris Pharma INC | $18.81 | 2024 | Dyanavel Xr |
| Indivior INC. | $18.61 | 2023 | Perseris |
| Noven Therapeutics, LLC | $13.85 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Strieter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.